Hologic (HOLX) Competitors $67.16 +0.34 (+0.51%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$65.12 -2.04 (-3.03%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HOLX vs. HQY, HSIC, MASI, MMSI, ALC, AMN, AVNS, HAE, PEN, and ZBHShould you be buying Hologic stock or one of its competitors? The main competitors of Hologic include HealthEquity (HQY), Henry Schein (HSIC), Masimo (MASI), Merit Medical Systems (MMSI), Alcon (ALC), AMN Healthcare Services (AMN), Avanos Medical (AVNS), Haemonetics (HAE), Penumbra (PEN), and Zimmer Biomet (ZBH). These companies are all part of the "medical" sector. Hologic vs. Its Competitors HealthEquity Henry Schein Masimo Merit Medical Systems Alcon AMN Healthcare Services Avanos Medical Haemonetics Penumbra Zimmer Biomet HealthEquity (NASDAQ:HQY) and Hologic (NASDAQ:HOLX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk. Is HQY or HOLX more profitable? Hologic has a net margin of 13.79% compared to HealthEquity's net margin of 9.80%. Hologic's return on equity of 19.69% beat HealthEquity's return on equity.Company Net Margins Return on Equity Return on Assets HealthEquity9.80% 11.01% 6.77% Hologic 13.79%19.69%10.82% Which has more volatility and risk, HQY or HOLX? HealthEquity has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Hologic has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Do insiders & institutionals have more ownership in HQY or HOLX? 99.6% of HealthEquity shares are held by institutional investors. Comparatively, 94.7% of Hologic shares are held by institutional investors. 1.5% of HealthEquity shares are held by company insiders. Comparatively, 1.9% of Hologic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, HQY or HOLX? Hologic has higher revenue and earnings than HealthEquity. Hologic is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHealthEquity$1.20B6.56$96.70M$1.3766.47Hologic$4.03B3.71$789.50M$2.3728.34 Does the media refer more to HQY or HOLX? In the previous week, Hologic had 25 more articles in the media than HealthEquity. MarketBeat recorded 32 mentions for Hologic and 7 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.68 beat Hologic's score of 0.94 indicating that HealthEquity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hologic 14 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend HQY or HOLX? HealthEquity presently has a consensus target price of $118.55, indicating a potential upside of 30.18%. Hologic has a consensus target price of $76.42, indicating a potential upside of 13.78%. Given HealthEquity's stronger consensus rating and higher possible upside, equities research analysts clearly believe HealthEquity is more favorable than Hologic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HealthEquity 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Hologic 0 Sell rating(s) 10 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.47 SummaryHealthEquity and Hologic tied by winning 8 of the 16 factors compared between the two stocks. Get Hologic News Delivered to You Automatically Sign up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOLX vs. The Competition Export to ExcelMetricHologicMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.89B$6.77B$5.48B$9.51BDividend YieldN/A1.32%4.73%4.08%P/E Ratio27.8720.9428.6723.80Price / Sales3.7154.14373.9066.65Price / Cash12.1520.5035.4557.96Price / Book3.094.468.275.55Net Income$789.50M$174.54M$3.24B$259.03M7 Day Performance0.99%-5.27%-3.69%-4.59%1 Month Performance2.85%-3.94%4.33%4.46%1 Year Performance-19.70%8.26%25.95%18.03% Hologic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOLXHologic4.8701 of 5 stars$67.16+0.5%$76.42+13.8%-19.3%$14.89B$4.03B27.877,063Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHQYHealthEquity3.7367 of 5 stars$95.76-0.3%$118.55+23.8%+16.9%$8.28B$1.20B69.903,120Positive NewsGap DownHSICHenry Schein4.1322 of 5 stars$70.46-1.4%$78.08+10.8%-6.6%$8.58B$12.67B22.0225,000Upcoming EarningsMASIMasimo3.6895 of 5 stars$162.18-1.5%$191.60+18.1%+43.4%$8.79B$2.09B-17.695,600Positive NewsUpcoming EarningsMMSIMerit Medical Systems4.5585 of 5 stars$84.46-0.3%$109.11+29.2%+0.8%$4.99B$1.39B41.407,400Trending NewsEarnings ReportAnalyst ForecastALCAlcon2.4531 of 5 stars$90.11-1.9%$106.13+17.8%-6.4%$44.45B$9.91B40.0525,599AMNAMN Healthcare Services4.496 of 5 stars$19.71-0.5%$32.08+62.8%-73.3%$754.42M$2.98B-4.552,968Upcoming EarningsAVNSAvanos Medical2.3325 of 5 stars$12.02+0.1%N/A-53.7%$555.85M$689.20M-1.442,227News CoverageUpcoming EarningsHAEHaemonetics4.8133 of 5 stars$74.66-0.7%$97.30+30.3%-17.2%$3.59B$1.36B22.563,023News CoveragePositive NewsUpcoming EarningsPENPenumbra4.6143 of 5 stars$229.90-1.4%$305.07+32.7%+41.6%$8.90B$1.19B216.894,500Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionZBHZimmer Biomet4.8434 of 5 stars$95.94-1.7%$111.39+16.1%-18.4%$18.98B$7.70B21.2317,000Positive NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies HealthEquity Alternatives Henry Schein Alternatives Masimo Alternatives Merit Medical Systems Alternatives Alcon Alternatives AMN Healthcare Services Alternatives Avanos Medical Alternatives Haemonetics Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOLX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hologic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hologic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
